Shares of Horizon Pharma PLC (NASDAQ:HZNP) have received an average rating of “Buy” from the fourteen analysts that are currently covering the firm. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $29.70.
Several brokerages recently commented on HZNP. Jefferies Group LLC set a $26.00 price target on shares of Horizon Pharma PLC and gave the company a “buy” rating in a research report on Wednesday, April 12th. BMO Capital Markets restated a “buy” rating and issued a $24.00 price target on shares of Horizon Pharma PLC in a research report on Wednesday, March 29th. Piper Jaffray Companies reduced their price target on shares of Horizon Pharma PLC from $32.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, March 24th. Mizuho reduced their price target on shares of Horizon Pharma PLC from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Tuesday, February 28th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $20.00 price target on shares of Horizon Pharma PLC in a research report on Tuesday, February 28th.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) traded down 1.90% during trading on Wednesday, hitting $14.95. The stock had a trading volume of 1,153,852 shares. The stock’s 50-day moving average is $15.02 and its 200-day moving average is $16.96. The stock’s market cap is $2.43 billion. Horizon Pharma PLC has a 12-month low of $13.05 and a 12-month high of $23.44.
Horizon Pharma PLC (NASDAQ:HZNP) last released its earnings results on Monday, February 27th. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.51 by $0.13. Horizon Pharma PLC had a negative net margin of 1.34% and a positive return on equity of 22.73%. The business earned $310.30 million during the quarter, compared to analyst estimates of $307.93 million. During the same period in the prior year, the business earned $0.63 earnings per share. The business’s quarterly revenue was up 26.9% on a year-over-year basis. On average, equities research analysts expect that Horizon Pharma PLC will post $2.16 EPS for the current year.
In other Horizon Pharma PLC news, EVP Robert Carey sold 31,808 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $16.03, for a total value of $509,882.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.10% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its position in shares of Horizon Pharma PLC by 7.4% in the third quarter. Bank of New York Mellon Corp now owns 750,930 shares of the biopharmaceutical company’s stock worth $13,614,000 after buying an additional 51,860 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Horizon Pharma PLC by 10.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 4,057,096 shares of the biopharmaceutical company’s stock worth $73,555,000 after buying an additional 383,892 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Horizon Pharma PLC during the fourth quarter worth approximately $1,702,000. Teachers Advisors LLC raised its position in shares of Horizon Pharma PLC by 235.7% in the third quarter. Teachers Advisors LLC now owns 864,348 shares of the biopharmaceutical company’s stock worth $15,671,000 after buying an additional 606,842 shares in the last quarter. Finally, BlackRock Fund Advisors raised its position in shares of Horizon Pharma PLC by 5.6% in the third quarter. BlackRock Fund Advisors now owns 7,052,901 shares of the biopharmaceutical company’s stock worth $127,869,000 after buying an additional 374,765 shares in the last quarter. 88.09% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was posted by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/brokerages-set-horizon-pharma-plc-hznp-pt-at-30-00-updated-updated/525324.html.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with our FREE daily email newsletter.